TrialClinical and translational science2023

A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.

Nicholas S Jones et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.